The current status and future perspectives on the management of stage III NSCLC: A focus on unresectable cancer treatment paradigms

Volume 123 | Supplement 1

Guest Editor: Dr Luis Paz-Ares; Organiser: AstraZeneca UKMC

This supplement reviews the rationale of current and future treatment strategies for unresectable Stage III non-small cell lung cancer (NSCLC). The included articles review concurrent chemoradiotherapy (cCRT), including updated administration techniques, the introduction of immunotherapy and practical implications to current treatment strategies.

Sponsorship Statement: This promotional supplement has been commissioned and funded by AstraZeneca UK Limited (“AstraZeneca”). AstraZeneca suggested the topics for the supplement, selected the authors, made honoraria payments to the authors, provided editorial comments and a full technical and medical review of the materials included within the supplement.

Date of preparation: December 2020 / GB-25434

Prescribing information and Adverse Event Reporting can be found here and on the final page of each article.